Inoviq Ltd (AU:IIQ) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inoviq Ltd has announced a breakthrough in ovarian cancer testing, with its EXO-OC blood test achieving over 94% accuracy in independent patient validation. This promising development could revolutionize early-stage ovarian cancer detection, crucially improving patient outcomes and survival rates. The company plans to optimize the test for commercial use and further clinical validation.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.